Journal
ANNUAL REVIEW OF MEDICINE, VOL 69
Volume 69, Issue -, Pages 421-436Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-052716-031710
Keywords
viral latency; HIV-1 reservoir; shock and kill; latency reversal agents; disulfiram; ingenol; benzotriazole; SMAC; NF-kappa B; protein kinase C; STAT5
Categories
Funding
- Doris Duke Charitable Foundation [2016102] Funding Source: Medline
- NHLBI NIH HHS [R01 HL126547] Funding Source: Medline
- NIAID NIH HHS [R01 AI124843, R33 AI122377, UM1 AI126620, R21 AI122377] Funding Source: Medline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL126547] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI126620, R21AI122377, R33AI122377, R01AI124843] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Antiretroviral therapy (ART) has rendered HIV-1 infection a treatable illness; however, ART is not curative owing to the persistence of replication-competent, latent proviruses in long-lived resting T cells. Strategies that target these latently infected cells and allow immune recognition and clearance of this reservoir will be necessary to eradicate HIV-1 in infected individuals. This review describes current pharmacologic approaches to reactivate the latent reservoir so that infected cells can be recognized and targeted, with the ultimate goal of achieving an HIV-1 cure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
